12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Other News

Spectrum Pharmaceuticals cancer news

Spectrum said that the U.S. Patent and Trademark Office (PTO) extended by five years U.S. Patent No. 6,028,071 covering cancer drug Folotyn pralatrexate. The extension postpones the original July 16, 2017, expiration date to...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >